Antimicrob Resist Infect Control:中国北京某一三级医院医疗相关感染的发病率

2020-04-06 MedSci原创 MedSci原创

本研究旨在利用中国北京某三级医院的实时HAI电子监控系统,对所有医疗卫生相关感染(HAI)的5年发病率趋势进行量化分析。

本研究旨在利用中国北京某三级医院的实时HAI电子监控系统,对所有医疗卫生相关感染(HAI)的5年发病率趋势进行量化分析。

 

通过实时监控系统通过扫描医院与HAI相关的电子数据库(如微生物报告、抗生素使用情况等)来识别HAI病例。对2013年1月1日-2017年12月31日期间,从监测系统导出的各类HAI住院患者的数据进行回顾性二次分析。HAI的发病率被定义为每1000个患者日的HAI数量。采用负二项式回归对发病率数据进行建模。

 

结果,5年期间共从633990例患者中发现23361例HAI,跨越6242375个患者日。总的来说,校正后的5年HAI发病率从2013年(每1000个患者日4.10例)到2017年(每1000个患者日3.62例)有小幅下降。呼吸道感染的发病率明显下降。但是,血行感染和手术部位感染的发生率明显增加。其中,呼吸道感染(43.80%)占HAIs的比重最大,其次是血行感染(15.74%),尿路感染(12.69%)。成人和老年患者中出现了夏季HAIs的高峰。

 

总之,本研究表明,基于现有医院电子数据库的连续电子发病率监测可以为测量全院HAI发病率提供一个实用的手段。估计的发病率趋势表明,有必要改进与血源性感染、呼吸机相关的肺炎、非重症监护病人和非设备相关的HAI的感染控制措施,尤其是在夏季的几个月里,有必要改进。

 

原始出处:

 

Yuzheng ZhangMingmei Du, et al., Incidence of healthcare-associated infections in a tertiary hospital in Beijing, China: results from a real-time surveillance system. Antimicrob Resist Infect Control. 2019; 8: 145. doi: 10.1186/s13756-019-0582-7

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084582, encodeId=74d220845820e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jun 15 15:00:18 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689567, encodeId=9855168956ef9, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu May 07 01:00:18 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857877, encodeId=f46b185e87796, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Feb 09 12:00:18 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823621, encodeId=ae75182362158, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Oct 25 14:00:18 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588424, encodeId=39a6158842454, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Apr 08 05:00:18 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-06-15 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084582, encodeId=74d220845820e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jun 15 15:00:18 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689567, encodeId=9855168956ef9, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu May 07 01:00:18 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857877, encodeId=f46b185e87796, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Feb 09 12:00:18 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823621, encodeId=ae75182362158, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Oct 25 14:00:18 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588424, encodeId=39a6158842454, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Apr 08 05:00:18 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084582, encodeId=74d220845820e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jun 15 15:00:18 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689567, encodeId=9855168956ef9, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu May 07 01:00:18 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857877, encodeId=f46b185e87796, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Feb 09 12:00:18 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823621, encodeId=ae75182362158, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Oct 25 14:00:18 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588424, encodeId=39a6158842454, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Apr 08 05:00:18 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084582, encodeId=74d220845820e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jun 15 15:00:18 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689567, encodeId=9855168956ef9, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu May 07 01:00:18 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857877, encodeId=f46b185e87796, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Feb 09 12:00:18 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823621, encodeId=ae75182362158, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Oct 25 14:00:18 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588424, encodeId=39a6158842454, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Apr 08 05:00:18 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2084582, encodeId=74d220845820e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Jun 15 15:00:18 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689567, encodeId=9855168956ef9, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Thu May 07 01:00:18 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857877, encodeId=f46b185e87796, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Feb 09 12:00:18 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823621, encodeId=ae75182362158, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Oct 25 14:00:18 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588424, encodeId=39a6158842454, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Wed Apr 08 05:00:18 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-04-08 skhzy

相关资讯

Mitochondrion:887名中国听力损失患者中的线粒体tRNA变异分析

线粒体tRNA变异是听力损失的重要诱因。然而,到目前为止只鉴定了一部分案例,且线粒体tRNA变异在听力损伤患者中的患病率仍旧不清楚。

MERS发现MERS零号病人的病毒学家扎基:中国做法值得借鉴

新华社开罗3月9日消息,埃及著名病毒学家、中东呼吸综合征“零号病人”发现者阿里·穆罕默德·扎基日前在开罗接受新华社记者专访时说,各国当前应将控制传染

中国首次出现2例境外输入新冠肺炎病例,均自伊朗入境

 MedSci小编注:中国的疫情整体控制良好,但是国外很多国家疫情逐步呈现失控状态。现在国内怕的不是我们国内自身“倒春寒”,而是怕境外输入!实际上,按基因组学的研究结果,境外的新冠肺炎的病毒与国内的毒株有一定的差异,也意味着境外毒株输入以后呈现的疾病特征,也许有一定差别,对诊治会带来哪些影响,也值得关注。此次2例输入北京,属于标志性事件,也提醒我们防疫,不仅仅要防国内,还要防国际。2月2

2020世界肾脏日:中国在行动

2020年3月12日是第15个世界肾脏日,中国上下都在防控新冠肺炎疫情期间。在这样一个非常时刻,根据大众对健康的迫切需求,仍不能忘记高举健康中国的伟大旗帜,要把防治慢性肾脏病的科普知识,通过这&ldq

中国批准将罗氏的白细胞介素-6单抗Actemra,用于控制新型冠状病毒感染患者体内的炎症风暴

中国已经批准在具有肺部并发症的冠状病毒患者中使用罗氏的抗炎药Actemra(tocilizumab)(一种靶向白介素6的单抗)。先前的研究表明,这类患者血液中IL-6水平显着升高,并且IL-6水平的升高(炎症和高水平的免疫反应的生物标志物)与新型冠状病毒感染肺炎患者的死亡率升高密切相关。

Allergy:青蒿素舌下免疫疗法治疗季节过敏性鼻炎试验

青蒿素是中国北方季节过敏性鼻炎(SAR)的一种重要秋季花粉过敏原。目前,还没有研究调查青蒿素过敏原免疫治疗情况。最近,有研究人员调查了青蒿素舌下免疫治疗(SLIT)的疗效和潜在机制。研究是一个随机、双盲和安慰剂对照III期临床试验,包括了71名SAR患者;并随机分配到青蒿提取物SLIT治疗组(n=47)或者安慰剂组(n=24),治疗进行的时间为32周。研究发现,在第一次花粉峰值阶段(1st PPP